Med-Ex Learning in collaboration with the European Charcot Foundation (ECF) and Fondazione Prada-Human Brains, conducted a live, in presence course that was also accessible via online attendance. This event was be held prior to the ECTRIMS Congress.

 

post-event resources

 

The slide kits and the video-lectures from this educational activity are available. Please click here to access these FREE resources.

 

OVERVIEW

 

Building on recent advancements in knowledge of pathogenic mechanisms and care of Multiple
Sclerosis, this annual course aimed to summarise all the main novelties of the year in the
field of MS. Particularly, this edition of the meeting focussed on the pathogenetic mechanisms
leading to neurodegeneration and clinical progression occurring inside the CNS, on the
strategies to prevent MS worsening and promote repair, as well as on the digital tools suitable
to measure disability progression. The ‘controversies’ session covered ‘hot topics’ for future
debate including clinical trial design in progressive MS patients, the role of artificial intelligence
in improving MS prediction, or the prognostic role of chronic active lesions quantification. The
course presented the contribution of the world leading experts in each field of interest, which created
for participants the opportunity to engage with inspiring researchers which are animating the
current scientific scene in MS.

 

Accreditation

 

The 2023 Joint Pre-ECTRIMS course, Milan, Italy 10/10/2023 - 10/10/2023, was  accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 5.5 European CME credits (ECMEC®s). Each medical specialist could claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at https://edhub.ama-assn.org/pages/applications.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

 

ENDORSEMENT

 

This educational activity was endorsed by ECTRIMS, MENACTRIMS, EAN and SIN.

 

Learning objectives

 

• Describe the role of new immunological players, like microglia, in MS development
• Illustrate mechanisms of action and safety profile of new MS treatments for relapsing remitting and progressive MS
• Describe the role of chronic active lesions in sustaining progression
• Discuss how to apply artificial intelligence to improve disability prediction

 

SCIENTIFIC agenda

 

Welcome & Opening
10.00 G. Comi (Italy) and X. Montalban (Spain)

 

Session 1: Advancements in understanding Multiple Sclerosis

Chair: G Comi (Italy)

 

10.15 L1 - Is the Epstein Barr Virus the trigger and/or the driver of MS?

G. Giovannoni (UK)

 

10.35 L2 - Tissue-resident immune cells in the pathogenesis of MS

 H. Lassmann (Austria)

 

10.55 L3 - MRI biomarkers of progression in MS 

C. Granziera (Switzerland)

 

11.15 Coffee break

11.45 L4 - Discontinuing MS treatments in a stable disease: yes, or no?

M. Tintorè (Spain)

12.05 L5 - Current and future treatments in Relapsing MS

X. Montalban (Spain)

 

12.25 L6 - Current and future treatments in Progressive MS

 G. Comi (Italy)

 

12.45 L7 - Enhancing myelin repair

B. Stankoff (France)

 

13.05 Q&A

 

13.30 Lunch

 

Session 2: Burning questions in MS

Chair: X. Montalban (Spain)

 

14.30 D1 - PIRA: mechanistic or statistical construct?

C. Tur (Spain) - F. Lublin (USA)

 

15.00 L8 - Immunosenescence: friend or foe?

V. Van Pesch (Belgium)

 

15.20 L9 - Cognition in MS

M. P. Amato (Italy)

 

15.40 L10 - Digital medicine in MS

L. Leocani (Italy)

 

16.00 L11 - Use of Artificial intelligence in predicting prognosis in MS: values and limits

A.Eshaghi (UK)

 

16.20 Round Table: Observational real-world studies in MS: usefulness and criticism

J. Hillert (Sweden), T. Kalinchik (Australia), A. Signori (Italy), M.Trojano (Italy)

 

16.50 Q&A

17.20 Wrap-up

 

17.30 End of the day

 

Acknowledgements

 

This educational activity was made possible thanks to unrestricted educational grants from Roche and Sanofi.